- Gastrointestinal stromal tumors (GIST) are the most common tumors of the gastrointestinal tract, most frequently found in the stomach or small intestine.
- The American Cancer Society estimates that the total number of GIST cases each year in the United States range from about 4,000 to about 6,000 patients. We estimate a similar incidence rate may apply in European and other countries.
- Estimates for 5-year survival range from 48% to 90% depending upon the stage of the disease at diagnosis.
- Patients diagnosed early with localized GIST generally undergo surgical resection of their tumors.
- In surgically resected patients with KIT-driven GIST considered at a high risk of recurrence and in unresectable or metastatic patients, the initial treatment is the kinase inhibitor imatinib.
- However, there currently are no approved therapeutic options for PDGFRα-driven GIST that potently inhibit D842V mutations, which is the most common mutation. The primary PDGFRα mutations are mostly insensitive to imatinib and other drugs approved for GIST.
Ron’s Story"There have been a lot of ups and downs of my journey and sometimes I get a little frightened but through it all I've tried to stay positive. To be honest, it's difficult sometimes but I feel the longer I fight, the more opportunity there is for future medical solutions. My goal is to hang around long enough so that when researchers are successful, I'm successful. Hope is, and always will be, the magic ingredient... Keep hope alive." Watch his story
Our Fight for Patients – GIST
We believe there is a clear unmet need for effective and well tolerated options for patients with metastatic GIST beyond the first-line. Our goal at Deciphera is to provide a much-needed therapeutic option for these patients for whom there are existing agents with only limited benefit or no approved treatments.
On this page you may select links to content published by persons not affiliated with Deciphera. The views expressed in these materials are those of the author and do not reflect the views of Deciphera. Additionally, the information contained in these materials may not be current. Deciphera disavows any obligation to correct or to update the information contained in these materials.